Longeveron Inc. (NASDAQ: LGVN) announced today that Nirav Jhaveri has been appointed as Chief Financial Officer, principal financial officer, and principal accounting officer. The appointment follows the departure of Marie Washburn, who will revert to her prior position as Corporate Controller.
Jhaveri, a CFA charterholder with over 25 years of experience in capital markets and corporate finance, brings more than 15 years of biotech sector expertise to the role. His prior executive positions include CFO roles at Opus Genetics (NASDAQ: IRD), Insilico Medicine (HKEX: 3696.HK), and Journey Medical Corporation (NASDAQ: DERM), as well as business development experience at Fortress Biotech. He also held equity research and investment banking roles at Citigroup and Bank of America, respectively.
Longeveron is a clinical-stage biotechnology company focused on developing cellular therapies for rare pediatric and chronic aging-related conditions. Its lead investigational product, laromestrocel, is an allogeneic mesenchymal stem cell therapy designed to address four key indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy, and Aging-related Frailty.
The company's Phase 2b clinical trial evaluating laromestrocel for HLHS is expected to deliver top-line results in September 2026. Laromestrocel has secured five U.S. FDA designations for the HLHS program, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
Steven H. Willard, Longeveron's Chief Executive Officer, stated that Jhaveri's biotech finance and capital markets experience will support the company's advancement of stem cell therapy development across its four indications.
